GlassScriptPhysician profile
Mazer Ally
NPI 1902018666
$228,630.21
in general payments reported to CMS, 2019-2025
48 companies · $66K in 2025
The $66K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $31K · 2021: $19K · 2022: $11K · 2023: $18K · 2024: $34K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Travel and Lodging: $23K · Food and Beverage: $6,162 · Consulting Fee: $3,000 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $85,636.50 |
| Travel and Lodging | $22,572.27 |
| Food and Beverage | $6,162.16 |
| Consulting Fee | $3,000.00 |
| Education | $167.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $200,916.64 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $12,550.26 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $5,402.40 | 2019-2025 | Tremfya, Stelara |
| Eli Lilly and Company | $5,193.55 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $933.00 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $335.53 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $281.77 | 2024-2025 | Stelara, Tremfya |
| Cook Medical LLC | $245.82 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $212.78 | 2022-2025 | Dupixent, Evkeeza |
| Lilly USA, LLC | $198.77 | 2023-2025 | Omvoh |
| Qol Medical, LLC | $182.83 | 2019-2022 | |
| Genzyme Corporation | $159.17 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $157.56 | 2020-2023 | |
| Romark Laboratories, Lc | $156.10 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $154.10 | 2019-2024 | Rebyota |
Show all 46 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazer Ally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.